2025-11-03

Q3 2025 Results

Financial data not clearly visible in provided XBRL format

2025-08-01

Q2 2025 Results

Revenue and EPS data not clearly extractable from XBRL format provided

2025-05-01

Q1 2025 Results

2024-11-01

Q3 2024 Results

Financial figures not extractable from XBRL metadata provided

2024-08-01

Q2 2024 Results

2024-05-01

Q1 2024 Results

2025-02-18

FY2024 Results

📌 Multiple strategic acquisitions completed including Silk Road Medical (Sep 2024), Axonics (Nov 2024), and Intera Oncology (Nov 2024)

2025-11-19

2026 Compensation Plans Approved

Annual bonus plan with 0-225% payout range, performance shares tied to TSR and organic sales growth

2025-10-23

Director John E. Sununu Not Standing for Re-election

John E. Sununu departing 2026 Annual Meeting after 17 years

2025-10-22

Q3 Earnings

Q3 2025 financial results for quarter ended Sept 30, 2025

2025-09-04

EVP Peripheral Interventions Retired

Jeffrey B. Mirviss retiring Dec 1, 2025, $705K base salary

2025-07-23

Q2 Earnings

Q2 2025 financial results announced

2025-05-28

Discontinued ACURATE Valve Systems

Worldwide discontinuation of ACURATE neo2 and Prime Aortic Valve Systems

2025-05-06

2025 Annual Shareholder Meeting Results

All 10 directors elected, say-on-pay approved, simple majority vote proposal passed

2025-04-23

CFO Transition

Daniel Brennan retiring as CFO, Jonathan Monson promoted effective June 30

2025-04-23

Q1 2025 Earnings

Q1 2025 financial results announced

2025-02-26

Euro Debt Offering

€1.5B notes issued (€850M 2031 at 3.0%, €650M 2034 at 3.25%)

2025-02-12

Director Not Standing for Re-election

Charles J. Dockendorff stepping down after 10 years

2025-02-05

Q4 2024 Earnings

Q4 and full year 2024 financial results announced

2025-01-16

LOTUS Edge Valve Settlement

Court preliminary approval Jan 8, final hearing Mar 25

2024-11-22

2025 Compensation Plans Approved

Annual bonus plan with 0-225% payout range, performance shares with 0-200% range

2024-11-15

Acquired Axonics Inc

$3.7B equity value, $71/share cash

2024-11-07

Resumed AVANT GUARD Clinical Trial

Trial studying drug-naïve patients with persistent atrial fibrillation resumed after data monitoring committee assessment

2024-10-23

Q3 Earnings

Q3 2024 financial results for quarter ended Sept 30

2024-07-30

New Director Appointed

David C. Habiger appointed to Board, ~$256K prorated compensation

2024-07-24

Q2 2024 Earnings

Q2 2024 financial results announced

2024-05-10

New Director Appointed & Credit Line Extended

Dr. Cheryl Pegus joins board, $2.75B credit facility extended to 2029

2024-05-06

Annual Shareholder Meeting

9 directors elected, bylaws amended for proxy rules

2024-04-24

Q1 Earnings

Q1 2024 financial results for quarter ended March 31, 2024